lncRNA FLVCR1‑AS1 regulates cell proliferation, migration and invasion by sponging miR‑485‑5p in human cholangiocarcinoma

Bao,Wenqing; Cao,Feng; Ni,Shubin; Yang,Jing; Li,Haidong; Su,Zhenxi; Zhao,Bin

doi:10.3892/ol.2019.10577

lncRNA FLVCR1‑AS1 regulates cell proliferation, migration and invasion by sponging miR‑485‑5p in human cholangiocarcinoma

Authors:
- Wenqing Bao
- Feng Cao
- Shubin Ni
- Jing Yang
- Haidong Li
- Zhenxi Su
- Bin Zhao
View Affiliations

Affiliations: Department of General Surgery, Shanghai Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200135, P.R. China
Published online on: July 5, 2019 https://doi.org/10.3892/ol.2019.10577
Pages: 2240-2247
Copyright: © Bao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA (lncRNA) FLVCR1 antisense RNA 1 (FLVCR1‑AS1) serves a crucial role in many types of cancer; however, to the best of our knowledge, the biological effect of FLVCR1‑AS1 in cholangiocarcinoma (CCA) remains unclear. The present study aimed to elucidate the involvement of FLVCR1‑AS1 in the regulation of human CCA cell growth, migration and invasion, as well as the mechanisms underlying its effect. The expression levels of FLVCR1‑AS1 in CCA tumor tissues, adjacent normal tissues, CCA cell lines and a cholangiocyte cell line were determined by reverse transcription‑quantitative polymerase chain reaction. A significantly higher expression level of FLVCR1‑AS1 was identified in CCA tumor tissues and the CCA cell lines HuCCT1 and CCLP1 compared with the normal controls. Short hairpin RNA targeting FLVCR1‑AS1 (shFLVCR1‑AS1) and a control plasmid (shNC) were transfected into CCA cell lines. Cell proliferation, colony formation, migration and invasion of CCA cells transfected with shFLVCR1‑AS1 were significantly suppressed compared with the shNC groups. The expression levels of migration and invasion‑associated proteins, including Twist, matrix metalloproteinase (MMP)‑2 and MMP‑9, were also significantly suppressed by shFLVCR1‑AS1‑treatment. Furthermore, FLVCR1‑AS1 knockdown inhibited tumor growth in a xenograft model. Mechanistically, FLVCR1‑AS1 was demonstrated to sponge microRNA‑485‑5p (miR‑485‑5p) in human CCA. The expression of miR‑458‑5p was significantly decreased in CCA tissue compared with normal tissue, and Pearson's correlation analysis revealed that FLVCR1‑AS1 expression was negatively correlated with miR‑485‑5p expression in CCA tissues. These results suggested that lncRNA FLVCR1‑AS1 may be used as a novel therapeutic target and a potential diagnostic marker for CCA.

View Figures

View References

1	Yang J, Liu Y, Wang B, Lan H, Liu Y, Chen F, Zhang J and Luo J: Sumoylation in p27kip1 via RanBP2 promotes cancer cell growth in cholangiocarcinoma cell line QBC939. BMC Mol Biol. 18:232017. View Article : Google Scholar : PubMed/NCBI
2	Sha M, Jeong S and Xia Q: Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns. J Hepatol. 68:1315–1316. 2018. View Article : Google Scholar : PubMed/NCBI
3	Jin Y, Gao J, Weng Q, Xiong F, Gu S, Shivaram G, Zhang F and Yang X: Cholangiocarcinoma: Molecular imaging-guided radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus thymidine kinase gene therapy. Am J Cancer Res. 8:502–513. 2018.PubMed/NCBI
4	Suksawat M, Techasen A, Namwat N, Boonsong T, Titapun A, Ungarreevittaya P, Yongvanit P and Loilome W: Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines-a new strategy for therapy. FEBS Open Bio. 8:513–522. 2018. View Article : Google Scholar : PubMed/NCBI
5	Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S and Shibata T: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer. 100:1257–1266. 2009. View Article : Google Scholar : PubMed/NCBI
6	Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; Cancer Genome Atlas Research Network, ; et al: Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context. Cell Rep. 23:297–312.e12. 2018. View Article : Google Scholar : PubMed/NCBI
7	Vrba L and Futscher BW: Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types. F1000Res. 7:2112018. View Article : Google Scholar : PubMed/NCBI
8	Zhang G, Pian C, Chen Z, Zhang J, Xu M, Zhang L and Chen Y: Identification of cancer-related miRNA-lncRNA biomarkers using a basic miRNA-lncRNA network. PLoS One. 13:e1966812018.
9	Lou Y, Jiang H, Cui Z, Wang X, Wang L and Han Y: Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high-grade ovarian serous cancer. Int J Mol Med. 42:91–104. 2018.PubMed/NCBI
10	Sun T, Du SY, Armenia J, Qu F, Fan J, Wang X, Fei T, Komura K, Liu SX, Lee GM and Kantoff PW: Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. Oncogenesis. 7:302018. View Article : Google Scholar : PubMed/NCBI
11	Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
12	Lv L, Wei M, Lin P, Chen Z, Gong P, Quan Z and Tang Z: Integrated mRNA and lncRNA expression profiling for exploring metastatic biomarkers of human intrahepatic cholangiocarcinoma. Am J Cancer Res. 7:688–699. 2017.PubMed/NCBI
13	Guo L, Zhou Y, Chen Y, Sun H, Wang Y and Qu Y: LncRNA ASAP1-IT1 positively modulates the development of cholangiocarcinoma via hedgehog signaling pathway. Biomed Pharmacother. 103:167–173. 2018. View Article : Google Scholar : PubMed/NCBI
14	Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li C, Kang P, Leng K, Ji D, Li Z, et al: SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J Exp Clin Cancer Res. 37:812018. View Article : Google Scholar : PubMed/NCBI
15	Shi X, Zhang H, Wang M, Xu X, Zhao Y, He R, Zhang M, Zhou M, Li X, Peng F, et al: LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells. Oncotarget. 8:58394–58404. 2017.PubMed/NCBI
16	Zhang S, Xiao J, Chai Y, Du YY, Liu Z, Huang K, Zhou X and Zhou W: LncRNA-CCAT1 promotes migration, invasion, and EMT in intrahepatic cholangiocarcinoma through suppressing miR-152. Dig Dis Sci. 62:3050–3058. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zhang C, Li JY, Tian FZ, Zhao G, Hu H, Ma YF and Yang YL: LncRNA NEAT1 promotes growth and metastasis of cholangiocarcinoma cells. Oncol Res. 26:879–888. 2018. View Article : Google Scholar
18	Jiang XM, Li ZL, Li JL, Zheng WY, Li XH, Cui YF and Sun DJ: LncRNA CCAT1 as the unfavorable prognostic biomarker for cholangiocarcinoma. Eur Rev Med Pharmacol Sci. 21:1242–1247. 2017.PubMed/NCBI
19	Igami T, Ebata T, Yokoyama Y, Sugawara G, Takahashi Y and Nagino M: Staging of peripheral-type intrahepatic cholangiocarcinoma: Appraisal of the new TNM classification and its modifications. World J Surg. 35:2501–2509. 2011. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y and Li Z: MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression. Cell Death Dis. 7:e21592016. View Article : Google Scholar : PubMed/NCBI
22	Jing LL and Mo XM: Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer. Eur Rev Med Pharmacol Sci. 20:1516–1520. 2016.PubMed/NCBI
23	Zheng B, Jeong S, Zhu Y, Chen L and Xia Q: miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA). Oncotarget. 8:100819–100830. 2017.PubMed/NCBI
24	Zhang K, Zhao Z, Yu J, Chen W, Xu Q and Chen L: LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cell Biochem. 119:6045–6056. 2018. View Article : Google Scholar : PubMed/NCBI
25	Liu B, Yan S, Jia Y, Ma J, Wu S, Xu Y, Shang M and Mao A: TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses. FEBS J. 283:3839–3850. 2016. View Article : Google Scholar : PubMed/NCBI
26	Ince AT, Yildiz K, Gangarapu V, Kayar Y, Baysal B, Karatepe O, Kemik AS and Şentürk H: Serum and biliary MMP-9 and TIMP-1 concentrations in the diagnosis of cholangiocarcinoma. Int J Clin Exp Med. 8:2734–2740. 2015.PubMed/NCBI
27	Wang Q, Tang H, Yin S and Dong C: Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep. 29:2046–2052. 2013. View Article : Google Scholar : PubMed/NCBI
28	Wang M, Cai WR, Meng R, Chi JR, Li YR, Chen AX, Yu Y and Cao XC: miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin. Biochem Biophys Res Commun. 501:48–54. 2018. View Article : Google Scholar : PubMed/NCBI
29	Duan J, Zhang H, Li S, Wang X, Yang H, Jiao S and Ba Y: The role of miR-485-5p/NUDT1 axis in gastric cancer. Cancer Cell Int. 17:922017. View Article : Google Scholar : PubMed/NCBI
30	Kang M, Ren MP, Zhao L, Li CP and Deng MM: miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 7:2212–2222. 2015.PubMed/NCBI